Survanta 25 mg (Beractant) Suspension

Survanta 25 mg is a beractant suspension used for respiratory support in premature infants. This intratracheal medication helps improve lung function and reduce respiratory distress.

Survanta 25 mg is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed, leading to difficulty breathing. Survanta works by replacing natural surfactants in the lungs, which helps the lungs expand more easily. It is administered intratracheally, directly into the airways, to provide immediate support.

Common effects of Survanta 25 mg may include improved breathing and reduced need for ventilator support in premature infants. The medication helps the lungs function more effectively by reducing surface tension, making it easier for the infant to breathe. Some infants may experience mild side effects, but these are generally managed by healthcare providers.

Survanta 25 mg should be used under the supervision of a healthcare professional. It is important to follow the prescribed dosage and administration guidelines to ensure safety and effectiveness. Infants with certain medical conditions or allergies may require special monitoring. Always consult a healthcare provider before use.

Survanta 25 mg may interact with other medications or treatments. It is important to inform your healthcare provider about any other medications the infant is taking. Certain medications or substances may affect the effectiveness or safety of Survanta. Always follow the advice of a healthcare professional regarding potential interactions.